Home
Zogenix

Zogenix Market Share Analysis for November 2025

ucb is a global biopharma company focused on creating value for people living with severe diseases. learn more about how ucb delivers value for patients through its patient assistance program, treatment tracker and more.

Health > Biotechnology and Pharmaceuticals

Domainzogenix.com

Year Founded2006

Employees201 - 500

Annual Revenue$50M - $75M

Zogenix

Zogenix (including company regionals)

zogenix.com

See more website traffic and engagement information

Zogenix Revenue up to November 2025 is 50M - 75M

revenue generated by Zogenix top domains

Zogenix top domains revenue over 3 years

Revenue for Zogenix top domains

zogenix.com50M - 75M

See more with Sales Intelligence

Total visits to Zogenix's top domains

Understand Zogenix market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Zogenix's top domains

Analyze Zogenix engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Zogenix's top domains

See how Zogenix keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Zogenix top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Zogenix

These are the website technologies, by industry, used by Zogenix top domains

Marketing (3)

Google Marketing Platform

Advertising (2)

DoubleClick

Mobile (2)

Meta Viewport

Payment & Currencies (2)

Euro

More Technologies

8

See all

News & Signals from Zogenix

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsZogenix launched open-label extension study on Jan 1st '16.To assess the long-term efficacy and safety of Fintepla, Zogenix launched an open-label extension study (NCT02823145) in 2016.

NewsZogenix is developing therapies for Dravet syndrome.Tevard is exploring the use of its novel Suppressor tRNA, Enhancer tRNA, and mRNA Amplifier platforms in neurological disorders, heart disease, and muscular dystrophies; the company has partnered with Zogenix to develop therapies for Dravet syndrome and other genetic epilepsies.

NewsZogenix launches UMDF Pilot Genetic Testing Project.Biopharmaceutical company Zogenix announced the ‘UMDF Pilot Genetic Testing Project’, which provides free support for mitochondrial genetic disease testing through the United Mitochondrial Disease Foundation.